61849-14-7
Chemical Structure
Epoprostenol sodium
Synonym(s): Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan
- CAS No.: 61849-14-7
- Formula:C20H31NaO5
- Molecular Weight:374.45
IUPAC Name: sodium (Z)-5-((3aR,4R,5R,6aR)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoate
InChIKey: LMHIPJMTZHDKEW-XQYLJSSYSA-M
SMILES: CCCCC[C@H](O)/C=C/[C@@H]1[C@@]([C@]2([H])C[C@H]1O)([H])C/C(O2)=C/CCCC(O[Na])=O
Biological Activity: Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Epoprostenol sodium | 98.03% | Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Epoprostenol sodium (Standard) | ≥98% | Epoprostenol (sodium) (Standard) is the analytical standard of Epoprostenol (sodium). This product is intended for research and analytical applications. Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Provencher S, et al.Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterialhypertension. PLoS One. 2015 Mar 20;10(3):e0120657. [Content Brief]
- [2]. Lambert O, et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted[J]. Drug Design, Development and Therapy, 2012: 61-70. [Content Brief]
- [3]. Akagi S, et al. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension[J]. International journal of cardiology, 2013, 165(3): 499-505. [Content Brief]
